Evidence map›Paper›PMID 26167495›Full record

ReviewBioMed research international2015

Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme.

Liu Yang, Geng Guo, Xiao-yuan Niu, Jing Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. Review
  3. Immunotherapy in Glioblastoma.Cancer treatment and research · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Liu YangDepartment of Neurology, The First Hospital, Shanxi Medical University, No. 85 South Jie Fang Road, Taiyuan, Shanxi 030001, China.
Geng GuoDepartment of Neurosurgery, The First Hospital, Shanxi Medical University, No. 85 South Jie Fang Road, Taiyuan, Shanxi 030001, China.
Xiao-yuan NiuDepartment of Neurology, The First Hospital, Shanxi Medical University, No. 85 South Jie Fang Road, Taiyuan, Shanxi 030001, China.
Jing LiuDepartment of Neurosurgery, The First Hospital, Shanxi Medical University, No. 85 South Jie Fang Road, Taiyuan, Shanxi 030001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most malignant glioma and patients diagnosed with this disease had poor outcomes even treated with the combination of conventional treatment (surgery, chemotherapy, and radiation). Dendritic cells (DCs) are the most powerful antigen presenting cells and DC-based vaccination has the potential to target and eliminate GBM cells and enhance the responses of these cells to the existing therapies with minimal damage to the healthy tissues around them. It can enhance recognition of GBM cells by the patients' immune system and activate vast, potent, and long-lasting immune reactions to eliminate them. Therefore, this therapy can prolong the survival of GBM patients and has wide and bright future in the treatment of GBM. Also, the efficacy of this therapy can be strengthened in several ways at some degree: the manipulation of immune regulatory components or costimulatory molecules on DCs; the appropriate choices of antigens for loading to enhance the effectiveness of the therapy; regulation of positive regulators or negative regulators in GBM microenvironment.

Indexed as

Brain NeoplasmsDendritic CellsGlioblastomaImmunotherapyAnimalsHumansMiceModels, Immunological

Identifiers

PMID26167495
PMCPMC4488155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.